66 related articles for article (PubMed ID: 26842138)
1. The utility of molecular testing in the futility of definite therapy.
Joshi A; Noronha V; Ghosh J; Prabhash K
Indian J Cancer; 2014; 51(4):409. PubMed ID: 26842138
[No Abstract] [Full Text] [Related]
2. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
[No Abstract] [Full Text] [Related]
3. Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Wu SG; Shih JY; Yu CJ; Yang PC
J Thorac Oncol; 2008 Apr; 3(4):451-2. PubMed ID: 18379370
[No Abstract] [Full Text] [Related]
4. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of gefitinib and erlotinib.
Levêque D
Lancet Oncol; 2011 Nov; 12(12):1093. PubMed ID: 22041538
[No Abstract] [Full Text] [Related]
7. A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
Gautschi O; Zander T; Keller FA; Strobel K; Hirschmann A; Aebi S; Diebold J
J Thorac Oncol; 2013 May; 8(5):e43-4. PubMed ID: 23584301
[No Abstract] [Full Text] [Related]
8. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
9. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation.
Ohtsuka K; Ohnishi H; Kurai D; Matsushima S; Morishita Y; Shinonaga M; Goto H; Watanabe T
J Clin Oncol; 2011 Mar; 29(8):e191-2. PubMed ID: 21172876
[No Abstract] [Full Text] [Related]
10. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
11. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
12. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
13. Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.
Tamura T; Kagohashi K; Satoh H
Oncol Res Treat; 2015; 38(6):316-7. PubMed ID: 26045030
[No Abstract] [Full Text] [Related]
14. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Takahashi T; Yamamoto N; Nukiwa T; Mori K; Tsuboi M; Horai T; Masuda N; Eguchi K; Mitsudomi T; Yokota S; Segawa Y; Ichinose Y; Fukuoka M; Saijo N
Anticancer Res; 2010 Feb; 30(2):557-63. PubMed ID: 20332470
[TBL] [Abstract][Full Text] [Related]
15. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Iyevleva AG; Mitiushkina NV; Karaseva NA; Orlov SV; Volodina LN; Kulikova YE; Lozhkina AM; Ivantsov AO; Tiurin VI; Togo AV; Imyanitov EN
J Thorac Oncol; 2014 Apr; 9(4):e31-3. PubMed ID: 24736087
[No Abstract] [Full Text] [Related]
16. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
Dziadziuszko R; Siemiatkowska A; Limon J; Rzyman W; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
J Thorac Oncol; 2007 Jan; 2(1):91-2. PubMed ID: 17410018
[TBL] [Abstract][Full Text] [Related]
17. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
18. Improvement of psoriasis in a lung cancer patient treated with erlotinib.
Giroux Leprieur E; Friard S; Couderc LJ
Eur J Dermatol; 2010; 20(2):243-4. PubMed ID: 20123646
[No Abstract] [Full Text] [Related]
19. An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Chan AW; Tong JH; Lo SH; To KF
J Thorac Oncol; 2013 Dec; 8(12):e107-8. PubMed ID: 24389445
[No Abstract] [Full Text] [Related]
20. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
